(English) ORYZON shareholders approve listing to the Spanish Continuous Market

Date: 16.09.2015

The General Meeting of Shareholders of Oryzon, a clinical stage biopharmaceutical company focused on Epigenetics to develop therapies in oncology and neurodegenerative diseases, agreed to publicly trade 100% of the company’s shares in the Spanish Main Market.